文献速递肝病消化道肿瘤与早癌

NASH相关肝细胞癌中的肝因子与脂肪因子

Hepatokines and adipokines in NASH-related hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2020-11-05

本文综述了肝因子和脂肪因子在NAFLD/NASH相关肝细胞癌中的作用。NAFLD相关HCC可在无肝硬化肝脏中发生,其预后与病毒相关HCC无差异。现有数据支持肝因子和脂肪因子作为疾病进展标志物或NAFLD相关HCC早期标志物的潜在用途,尤其是血管生成素样蛋白、成纤维细胞生长因子和apelin。

要点

  • NAFLD相关HCC可在无肝硬化肝脏中发生,预后与病毒相关HCC无差异
  • 肝因子和脂肪因子可能作为NAFLD疾病进展或HCC早期标志物
  • 血管生成素样蛋白、成纤维细胞生长因子和apelin或可作为检测或治疗靶点

核心结论

  • 当前数据支持肝因子和脂肪因子可能用于NAFLD相关HCC的检测甚至作为治疗靶点。

研究设计与样本

  • 本文为综述,汇总支持肝因子和脂肪因子作为NAFLD疾病进展标志物或NAFLD相关HCC早期标志物的当前数据。

主要发现

  • NAFLD相关HCC可在无肝硬化肝脏中发生,且预后和生存与病毒相关HCC无差异。
  • 肝因子和脂肪因子可能作为NAFLD疾病进展的标志物或NAFLD相关HCC的早期标志物。
  • 尤其血管生成素样蛋白、成纤维细胞生长因子和apelin可能用于检测或作为治疗靶点。

临床怎么用

  • 肝因子和脂肪因子(尤其血管生成素样蛋白、成纤维细胞生长因子和apelin)或可用于NAFLD相关HCC的检测或作为治疗靶点。

局限性

  • 肝因子和脂肪因子改变的机制及相互作用尚需大量工作阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incidence of hepatocellular carcinoma (HCC) is increasing in industrialised societies; this is likely secondary to the increasing burden of non-alcoholic fatty liver disease (NAFLD), its progressive form non-alcoholic steatohepatitis (NASH), and the metabolic syndrome. Cumulative studies suggest that NAFLD-related HCC may also develop in non-cirrhotic livers. However, prognosis and survival do not differ between NAFLD- or virus-associated HCC. Thus, research has increasingly focused on NAFLD-related risk factors to better understand the biology of hepatocarcinogenesis and to develop new diagnostic, preventive, and therapeutic strategies. One important aspect thereof is the role of hepatokines and adipokines in NAFLD/NASH-related HCC. In this review, we compile current data supporting the use of hepatokines and adipokines as potential markers of disease progression in NAFLD or as early markers of NAFLD-related HCC. While much work must be done to elucidate the mechanisms and interactions underlying alterations to hepatokines and adipokines, current data support the possible utility of these factors - in particular, angiopoietin-like proteins, fibroblast growth factors, and apelin - for detection or even as therapeutic targets in NAFLD-related HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kucukoglu O, Sowa JP, Mazzolini GD, et al. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J Hepatol. 2020. PMID: 33161047. doi:10.1016/j.jhep.2020.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。